Nordex SE

  • WKN: A0D655
  • ISIN: DE000A0D6554
  • Land: Germany

Aktuelle Termine

15.11.21 Veröffentlichung Quartalsfinanzbericht (Stichtag Q3)
28.09.21 Analysts' Conference
25.08.21 Analysts' Conference
12.08.21 Veröffentlichung Halbjahresfinanzbericht
27.05.21 Analystenveranstaltung
26.05.21 Analystenveranstaltung
18.05.21 Analysts' Conference
12.05.21 Analysts' Conference
11.05.21 Veröffentlichung Quartalsfinanzbericht (Stichtag Q1)
05.05.21 Hauptversammlung
14.04.21 Analysts' Conference
30.03.21 Analysts' Conference
25.03.21 Analysts' Conference
23.03.21 Veröffentlichung Jahresfinanzbericht
17.02.21 Analystenveranstaltung
20.01.21 Analystenveranstaltung
12.01.21 Analystenveranstaltung
11.01.21 Analystenveranstaltung
13.11.20 Veröffentlichung Quartalsfinanzbericht (Stichtag Q3)
23.09.20 Analystenveranstaltung

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021